Mechanisms of apoptosis induction by simultaneous inhibition of PI3K and FLT3-ITD in AML cells in the hypoxic bone marrow microenvironment

Cancer Letters

Volumn 329, Issue 1, 2013, Pages 45-58

  Jin, Linhua ^a   Tabe, Yoko ^a,b   Lu, Hongbo ^b   Borthakur, Gautam ^b   Miida, Takashi ^a   Kantarjian, Hagop ^b   Andreeff, Michael ^b   Konopleva, Marina ^b  

^a JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Acute myeloid leukemia; Bone marrow microenvironment; GDC 0941; Hypoxia; Sorafenib

Indexed keywords

CD135 ANTIGEN; PHOSPHATIDYLINOSITOL 3 KINASE; PICTILISIB; PROTEIN KINASE B; PROTEIN KINASE PIM 1; PROTEIN MCL 1; SORAFENIB;

ACUTE GRANULOCYTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BONE MARROW CELL; CANCER COMBINATION CHEMOTHERAPY; CELL HYPOXIA; CELL VIABILITY; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; DRUG MECHANISM; DRUG STRUCTURE; ENZYME ACTIVATION; ENZYME INHIBITION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; STROMA CELL; TUMOR MICROENVIRONMENT;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BONE MARROW; CELL HYPOXIA; CELLULAR MICROENVIRONMENT; COCULTURE TECHNIQUES; ENZYME INHIBITORS; FMS-LIKE TYROSINE KINASE 3; HUMANS; INDAZOLES; LEUKEMIA, MYELOID, ACUTE; MUTATION; NIACINAMIDE; PHENYLUREA COMPOUNDS; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-BCL-2; PROTO-ONCOGENE PROTEINS C-PIM-1; STROMAL CELLS; SULFONAMIDES;

EID: 84871720541     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2012.09.020     Document Type: Article

References (51)

1. Kornblau S.M., Womble M., Qiu Y.H., Jackson C.E., Chen W., Konopleva M., Estey E.H., Andreeff M. Simultaneous activation of multiple signal transduction pathways confers poor prognosis in acute myelogenous leukemia. Blood 2006, 108:2358-2365.
2. Vivanco I., Sawyers C.L. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat. Rev. Cancer 2002, 2:489-501.
3. Hay N., Sonenberg N. Upstream and downstream of mTOR. Genes Dev. 2004, 18:1926-1945.
4. Tabe Y., Jin L., Tsutsumi-Ishii Y., Xu Y., McQueen T., Priebe W., Mills G.B., Ohsaka A., Nagaoka I., Andreeff M., Konopleva M. Activation of integrin-linked kinase is a critical prosurvival pathway induced in leukemic cells by bone marrow-derived stromal cells. Cancer Res. 2007, 67:684-694.
5. Z. Zeng, Y.X. Shi, T. Tsao, Y. Qiu, S.M. Kornblau, K.A. Baggerly, W. Liu, K. Jessen, Y. Liu, H. Kantarjian, C. Rommel, D.A. Fruman, M. Andreeff, M. Konopleva, Targeting of mTORC1/2 by the mTOR kinase inhibitor PP242 induces apoptosis in AML under conditions mimicking the bone marrow microenvironment, Blood (2012) e-pub.
6. Martelli A.M., Evangelisti C., Chiarini F., McCubrey J.A. The phosphatidylinositol 3-kinase/Akt/mTOR signaling network as a therapeutic target in acute myelogenous leukemia patients. Oncotarget 2010, 1:89-103.
7. Dunlop E.A., Tee A.R. Mammalian target of rapamycin complex 1: signaling inputs, substrates and feedback mechanisms. Cell. Signal. 2009, 21:827-835.
8. Hu L., Zaloudek C., Mills G.B., Gray J., Jaffe R.B. In vivo and in vitro ovarian carcinoma growth inhibition by a phosphatidylinositol 3-kinase inhibitor (LY294002). Clin. Cancer Res. 2000, 6:880-886.
9. Kong D., Yamori T. Advances in development of phosphatidylinositol 3-kinase inhibitors. Curr. Med. Chem. 2009, 16:2839-2854.
10. Folkes A.J., Ahmadi K., Alderton W.K., Alix S., Baker S.J., Box G., Chuckowree I.S., Clarke P.A., Depledge P., Eccles S.A., Friedman L.S., Hayes A., Hancox T.C., Kugendradas A., Lensun L., Moore P., Olivero A.G., Pang J., Patel S., Pergl-Wilson G.H., Raynaud F.I., Robson A., Saghir N., Salphati L., Sohal S., Ultsch M.H., Valenti M., Wallweber H.J., Wan N.C., Wiesmann C., Workman P., Zhyvoloup A., Zvelebil M.J., Shuttleworth S.J. The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer. J. Med. Chem. 2008, 51:5522-5532.
11. Gilliland D.G., Griffin J.D. The roles of FLT3 in hematopoiesis and leukemia. Blood 2002, 100:1532-1542.
12. Nakao M., Yokota S., Iwai T., Kaneko H., Horiike S., Kashima K., Sonoda Y., Fujimoto T., Misawa S. Internal tandem duplication of the flt3 gene found in acute myeloid leukemia. Leukemia 1996, 10:1911-1918.
13. Mizuki M., Fenski R., Halfter H., Matsumura I., Schmidt R., Müller C., Grüning W., Kratz-Albers K., Serve S., Steur C., Büchner T., Kienast J., Kanakura Y., Berdel W.E., Serve H. Flt3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the Ras and STAT5 pathways. Blood 2000, 96:3907-3914.
14. Choudhary C., Brandts C., Schwable J., Tickenbrock L., Sargin B., Ueker A., Böhmer F.D., Berdel W.E., Müller-Tidow C., Serve H. Activation mechanisms of STAT5 by oncogenic Flt3-ITD. Blood 2007, 110:370-374.
15. Radomska H.S., Bassères D.S., Zheng R., Zhang P., Dayaram T., Yamamoto Y., Sternberg D.W., Lokker N., Giese N.A., Bohlander S.K., Schnittger S., Delmotte M.H., Davis R.J., Small D., Hiddemann W., Gilliland D.G., Tenen D.G. Block of C/EBP alpha function by phosphorylation in acute myeloid leukemia with FLT3 activating mutations. J. Exp. Med. 2006, 203:371-381.
16. Shah N., Pang B., Yeoh K.G., Thorn S., Chen C.S., Lilly M.B., Salto-Tellez M. Potential roles for the PIM1 kinase in human cancer - a molecular and therapeutic appraisal. Eur. J. Cancer 2008, 44:2144-2151.
17. Amaravadi R., Thompson C.B. The survival kinases Akt and Pim as potential pharmacological targets. J. Clin. Invest. 2005, 115:2618-2624.
18. Lierman E., Lahortiga I., Van Miegroet H., Mentens N., Marynen P., Cools J. The ability of sorafenib to inhibit oncogenic PDGFRbeta and FLT3 mutants and overcome resistance to other small molecule inhibitors. Haematologica 2007, 92:27-34.
19. Metzelder S., Wang Y., Wollmer E., Wanzel M., Teichler S., Chaturvedi A., Eilers M., Enghofer E., Neubauer A., Burchert A. Compassionate use of sorafenib in FLT3-ITD-positive acute myeloid leukemia: sustained regression before and after allogeneic stem cell transplantation. Blood 2009, 113:6567-6571.
20. Zhang W., Konopleva M., Shi Y.X., McQueen T., Harris D., Ling X., Estrov Z., Quintás-Cardama A., Small D., Cortes J., Andreeff M. Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia. J. Natl. Cancer Inst. 2008, 100:184-198.
21. Borthakur G., Kantarjian H., Ravandi F., Zhang W., Konopleva M., Wright J.J., Faderl S., Verstovsek S., Mathews S., Andreeff M., Cortes J.E. Phase I study of sorafenib in patients with refractory or relapsed acute leukemias. Haematologica 2011, 96:62-68.
22. Zeng Z., Shi Y.X., Samudio I.J., Wang R.Y., Ling X., Frolova O., Levis M., Rubin J.B., Negrin R.R., Estey E.H., Konoplev S., Andreeff M., Konopleva M. Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML. Blood 2009, 113:6215-6224.
23. Eliasson P., Jönsson J.I. The hematopoietic stem cell niche: low in oxygen but a nice place to be. J. Cell. Physiol. 2010, 222:17-22.
24. Mortensen B.T., Jensen P.O., Helledie N., Iversen P.O., Ralfkiaer E., Larsen J.K., Madsen M.T. Changing bone marrow micro-environment during development of acute myeloid leukaemia in rats. Br. J. Haematol. 1998, 102:458-464.
25. Jensen P.O., Mortensen B.T., Hodgkiss R.J., Iversen P.O., Christensen I.J., Helledie N., Larsen J.K. Increased cellular hypoxia and reduced proliferation of both normal and leukaemic cells during progression of acute myeloid leukaemia in rats. Cell Prolif. 2000, 33:381-395.
26. Frolova O., Samudio I., Benito J.M., Jacamo R., Kornblau S.M., Markovic A., Schober W., Lu H., Qiu Y.H., Buglio D., McQueen T., Pierce S., Shpall E., Konoplev S., Thomas D., Kantarjian H., Lock R., Andreeff M., Konopleva M. Regulation of HIF-1α signaling and chemoresistance in acute lymphocytic leukemia under hypoxic conditions of the bone marrow microenvironment. Cancer Biol. Ther. 2012, 13:858-870.
27. Fiegl M., Samudio I., Mnjoyan Z., Korchin B., Fritsche H., Andreeff M. Physiological hypoxia promotes lipid raft and PI3K-dependent activation of MAPK 42/44 in leukemia cells. Leukemia 2010, 24:1364-1367.
28. Alvarez-Tejado M., Naranjo-Suarez S., Jiménez C., Carrera A.C., Landázuri M.O., del Peso L. Hypoxia induces the activation of the phosphatidylinositol 3-kinase/Akt cell survival pathway in PC12 cells: protective role in apoptosis. J. Biol. Chem. 2001, 276:22368-22374.
29. Tabe Y., Konopleva M., Munsell M.F., Marini F.C., Zompetta C., McQueen T., Tsao T., Zhao S., Pierce S., Igari J., Estey E.H., Andreeff M. PML-RARα is associated with leptin-receptor induction: the role of mesenchymal stem cell-derived adipocytes in APL cell survival. Blood 2004, 103:1815-1822.
30. Pittenger M.F., Mackay A.M., Beck S.C., Jaiswal R.K., Douglas R., Mosca J.D., Moorman M.A., Simonetti D.W., Craig S., Marshak D.R. Multilineage potential of adult human mesenchymal stem cells. Science 1999, 284:143-147.
31. Chou T.C., Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv. Enzyme Regul. 1984, 22:27-55.
32. Salphati L., Wong H., Belvin M., Bradford D., Edgar K.A., Prior W.W., Sampath D., Wallin J.J. Pharmacokinetic-pharmacodynamic modeling of tumor growth inhibition and biomarker modulation by the novel phosphatidylinositol 3-kinase inhibitor GDC-0941. Drug Metab. Dispos. 2010, 38:1436-1442.
33. Piloto O., Wright M., Brown P., Kim K.T., Levis M., Small D. Prolonged exposure to FLT3 inhibitors leads to resistance via activation of parallel signaling pathways. Blood 2007, 109:1643-1652.
34. Zeng Z., Samudio I.J., Zhang W., Estrov Z., Pelicano H., Harris D., Frolova O., Hail N., Chen W., Kornblau S.M., Huang P., Lu Y., Mills G.B., Andreeff M., Konopleva M. Simultaneous inhibition of PDK1/AKT and Fms-like tyrosine kinase 3 signaling by a small-molecule KP372-1 induces mitochondrial dysfunction and apoptosis in acute myelogenous leukemia. Cancer Res. 2006, 7:3737-3746.
35. Weisberg E., Banerji L., Wright R.D., Barrett R., Ray A., Moreno D., Catley L., Jiang J., Hall-Meyers E., Sauveur-Michel M., Stone R., Galinsky I., Fox E., Kung A.L., Griffin J.D. Potentiation of antileukemic therapies by the dual PI3K/PDK-1 inhibitor, BAG956: effects on BCR-ABL- and mutant FLT3-expressing cells. Blood 2008, 111:3723-3734.
36. Levis M., Ravandi F., Wang E.S., Baer M.R., Perl A., Coutre S., Erba H., Stuart R.K., Baccarani M., Cripe L.D., Tallman M.S., Meloni G., Godley L.A., Langston A.A., Amadori S., Lewis I.D., Nagler A., Stone R., Yee K., Advani A., Douer D., Wiktor-Jedrzejczak W., Juliusson G., Litzow M.R., Petersdorf S., Sanz M., Kantarjian H.M., Sato T., Tremmel L., Bensen-Kennedy D.M., Small D., Smith B.D. Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse. Blood 2011, 117:3294-3301.
37. Zheng R., Bailey E., Nguyen B., Yang X., Piloto O., Levis M., Small D. Further activation of FLT3 mutants by FLT3 ligand. Oncogene 2011, 30:4004-4014.
38. Konopleva M.Y., Jordan C.T. Leukemia stem cells and microenvironment: biology and therapeutic targeting. J. Clin. Oncol. 2011, 29:591-599.
39. Benito J., Shi Y., Szymanska B., Carol H., Boehm I., Lu H., Konoplev S., Fang W., Zweidler-McKay P.A., Campana D., Borthakur G., Bueso-Ramos C., Shpall E., Thomas D.A., Jordan C.T., Kantarjian H., Wilson W.R., Lock R., Andreeff M., Konopleva M. Pronounced hypoxia in models of murine and human leukemia: high efficacy of hypoxia-activated prodrug PR-104. PLoS One 2011, 6:e23108.
40. Azab A.K., Hu J., Quang P., Azab F., Pitsillides C., Awwad R., Thompson B., Maiso P., Sun J.D., Hart C.P., Roccaro A.M., Sacco A., Ngo H.T., Lin C.P., Kung A.L., Carrasco R.D., Vanderkerken K., Ghobrial I.M. Hypoxia promotes dissemination of multiple myeloma through acquisition of epithelial to mesenchymal transition-like features. Blood 2012, 119:5782-5794.
41. Lee S.M., Lee C.T., Kim Y.W., Han S.K., Shim Y.S., Yoo C.G. Hypoxia confers protection against apoptosis via PI3K/Akt and ERK pathways in lung cancer cells. Cancer Lett. 2006, 242:231-238.
42. Pouyssegur J., Dayan F., Mazure N.M. Hypoxia signalling in cancer and approaches to enforce tumour regression. Nature 2006, 441:437-443.
43. Chen E.Y., Mazure N.M., Cooper J.A., Giaccia A.J. Hypoxia activates a platelet-derived growth factor receptor/phosphatidylinositol 3-kinase/Akt pathway that results in glycogen synthase kinase-3 inactivation. Cancer Res. 2001, 61:2429-2433.
44. Vasseur S., Afzal S., Tardivel-Lacombe J., Park D.S., Iovanna J.L., Mak T.W. DJ-1/PARK7 is an important mediator of hypoxia-induced cellular responses. Proc. Natl. Acad. Sci. USA 2009, 106:1111-1116.
45. Sun H.L., Liu Y.N., Huang Y.T., Pan S.L., Huang D.Y., Guh J.H., Lee F.Y., Kuo S.C., Teng C.M. YC-1 inhibits HIF-1 expression in prostate cancer cells: contribution of Akt/NF-kappaB signaling to HIF-1alpha accumulation during hypoxia. Oncogene 2007, 26:3941-3951.
46. Raynaud F.I., Eccles S.A., Patel S., Alix S., Box G., Chuckowree I., Folkes A., Gowan S., De Haven Brandon A., Di Stefano F., Hayes A., Henley A.T., Lensun L., Pergl-Wilson G., Robson A., Saghir N., Zhyvoloup A., McDonald E., Sheldrake P., Shuttleworth S., Valenti M., Wan N.C., Clarke P.A., Workman P. Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941. Mol. Cancer Ther. 2009, 8:1725-1738.
47. Kojima K., Konopleva M., Tsao T., Andreeff M., Ishida H., Shiotsu Y., Jin L., Tabe Y., Nakakuma H. Selective FLT3 inhibitor FI-700 neutralizes Mcl-1 and enhances p53-mediated apoptosis in AML cells with activating mutations of FLT3 through Mcl-1/Noxa axis. Leukemia 2010, 24:33-43.
48. A.T. Fathi, O. Arowojolu, I. Swinnen, T. Sato, T. Rajkhowa, D. Small, F. Marmsater, J.E. Robinson, S.D. Gross, M. Martinson, S. Allen, N.C. Kallan, M. Levis, A potential therapeutic target for FLT3-ITD AML: PIM1 kinase, Leuk. Res. 27 (2011) [Epub ahead of print].
49. Chen L.S., Redkar S., Bearss D., Wierda W.G., Gandhi V. Pim kinase inhibitor, SGI-1776, induces apoptosis in chronic lymphocytic leukemia cells. Blood 2009, 114:4150-4157.
50. Warr M.R., Shore G.C. Unique biology of Mcl-1: therapeutic opportunities in cancer. Curr. Mol. Med. 2008, 8:138-147.
51. Jin L., Hope K.J., Zhai Q., Smadja-Joffe F., Dick J.E. Targeting of CD44 eradicates human acute myeloid leukemic stem cells. Nat. Med. 2006, 12:1167-1174.